Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • Evaluating Mutual Fund Risk-Return Tradeoffs: Key Metrics
    • XRP ETFs see steady inflows as total assets hit $1.2B
    • Gold ETFs Boom: GLD Is Larger in Size But AAAU Is More Affordable
    • ICICI Prudential MF enters SIF space with equity ex top 100, hybrid long short funds
    • Portfolio Stability With Dividend Yield Funds
    • A practical guide to small-cap fund investing
    • XRP’s Chance to Spike as ETFs Attract Major Funds
    • GIFT City Funds offer new route to global investing, says Daulat Finvest CEO
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»Funds»COSCIENS Biopharma – Conclusion d’un accord de résolution avec Goodwood, Goodwood Fund et Puccetti Funds Management
    Funds

    COSCIENS Biopharma – Conclusion d’un accord de résolution avec Goodwood, Goodwood Fund et Puccetti Funds Management

    May 30, 2025


    Logo COSCIENS Biopharma Inc.

    COSCIENS Biopharma Inc, anciennement Aeterna Zentaris Inc, est une société biopharmaceutique spécialisée dans le développement et la commercialisation d’un portefeuille diversifié de produits pharmaceutiques et diagnostiques, y compris ceux qui sont axés sur des domaines où les besoins médicaux ne sont pas satisfaits. Son produit principal, la macimoréline (Macrilen ; Ghryvelin), est un test oral indiqué pour le diagnostic de la déficience en hormone de croissance chez l’adulte (DHCA). La société est également engagée dans le développement d’actifs thérapeutiques et d’une technologie d’extraction propriétaire, qui est appliquée à la production d’ingrédients actifs à partir de ressources végétales renouvelables utilisées dans les produits cosméceutiques (c’est-à-dire le bêta-glucane d’avoine et les avenanthramides, que l’on trouve dans des marques de produits de soins de la peau comme Aveeno et Burt’s Bees) et qui sont en cours de développement en tant que nutraceutiques et/ou produits pharmaceutiques potentiels.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    Portfolio Stability With Dividend Yield Funds

    December 20, 2025

    A practical guide to small-cap fund investing

    December 20, 2025

    GIFT City Funds offer new route to global investing, says Daulat Finvest CEO

    December 20, 2025
    Leave A Reply Cancel Reply

    Top Posts

    The Shifting Landscape of Art Investment and the Rise of Accessibility: The London Art Exchange

    September 11, 2023

    Charlie Cobham: The Art Broker Extraordinaire Maximizing Returns for High Net Worth Clients

    February 12, 2024

    Gold ETFs Boom: GLD Is Larger in Size But AAAU Is More Affordable

    December 20, 2025

    The Unyielding Resilience of the Art Market: A Historical and Contemporary Perspective

    November 19, 2023
    Don't Miss
    Mutual Funds

    Evaluating Mutual Fund Risk-Return Tradeoffs: Key Metrics

    December 20, 2025

    One of the principles of investing is the risk-return tradeoff, defined as the correlation between…

    XRP ETFs see steady inflows as total assets hit $1.2B

    December 20, 2025

    Gold ETFs Boom: GLD Is Larger in Size But AAAU Is More Affordable

    December 20, 2025

    ICICI Prudential MF enters SIF space with equity ex top 100, hybrid long short funds

    December 20, 2025
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    Best mutual funds: Top 5 sectoral funds with up to 41% annualised returns in 5 years – Money News

    April 11, 2025

    Why I’m Loading Up on These 3 High-Dividend ETFs for Passive Income

    October 27, 2024

    As COVID relief funds dwindle, San Antonio and its nonprofits brace for the end of the line

    August 29, 2024
    Our Picks

    Evaluating Mutual Fund Risk-Return Tradeoffs: Key Metrics

    December 20, 2025

    XRP ETFs see steady inflows as total assets hit $1.2B

    December 20, 2025

    Gold ETFs Boom: GLD Is Larger in Size But AAAU Is More Affordable

    December 20, 2025
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    ₹10,000 monthly SIP in this mutual fund has grown to ₹1.52 crore in 22 years

    September 17, 2025
    © 2025 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.